BRANCHBURG, NJ--(Marketwire - September 10, 2012) -
Hydromer, Inc. (OTCQB: HYDI
) (PINKSHEETS: HYDI
) announced that during August of its first fiscal quarter, it had entered into two royalty bearing License Agreements, one with a US-based medical device company, and one with a China-based medical device company.
Under the terms of these agreements, each company is licensed to use certain proprietary Hydromer® medical coatings on medical devices, such as vascular access guidewires, nasogastic feeding catheters and gastrointestinal placement stylets.
"Hydromer's innovative medical coating technologies continue to gain interest in the evolving global medical device marketplace," commented Martin von Dyck, Executive Vice President of Hydromer, Inc., and President of the Biosearch Medical Products, Inc. subsidiary, adding, "Our continued success is propelled by our technologies versatility and performance, which is further complimented by our vast scope of international regulatory approvals, and bolstered by our ability to provide our clients with custom, 'turn-key,' validated coating equipment. Globally, our corporate culture is based on dynamic and collaborative relationship building, focusing on providing our clients impeccable quality at very competitive pricing."
About Hydromer, Inc.: Hydromer, Inc. is a bio-technology based company involved in the research and development, manufacture, contract coating and commercialization of specialized polymer and hydrogel products for medical device, animal health, cosmetic, personal care, and industrial uses. These technologies include Hydromer lubricious / anti-microbial / anti-thrombogenic / cell anti-mitosis / cell growth enhancing coatings for the medical marketplace.
For additional information please visit the following Web-site:
Hydromer ® is a registered trademark of Hydromer, Inc.